Open AccessPhase I Trial of Repeated Intrathecal Autologous Bone Marrow‐Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis
Author(s) -
Oh Ki-Wook,
Moon Chanil,
Kim Hyun Young,
Oh Sung-il,
Park Jinseok,
Lee Jun Ho,
Chang In Young,
Kim Kyung Suk,
Kim Seung Hyun
Publication year - 2015
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2014-0212
Subject(s) - medicine , amyotrophic lateral sclerosis , mesenchymal stem cell , adverse effect , clinical trial , surgery , bone marrow , cell therapy , stem cell , anesthesia , disease , pathology , biology , genetics
The aim of this open‐label phase I clinical trial is to evaluate the safety of two repeated intrathecal injections of autologous bone marrow (BM)‐derived mesenchymal stromal cells (MSCs) in amyotrophic lateral sclerosis patients. With the exception of 1 patient who died before the bone marrow extraction, no serious adverse events were observed during the follow‐up period. Two repeated intrathecal injections of autologous MSCs were safe and feasible throughout the duration of the 12‐month follow‐up period.